Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Catholic University of Leuven
VERSANT HIV drug resistance assay effective
January 14th, 2004
The VERSANT HIV drug resistance assay is suitable for clinical use. In a recent study, scientists "evaluated the performance of the VERSANT HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000." "We compared the results with population sequencing and found concordance to be in line with previous studies in treatment-experienced patients (86.87% for reverse transcriptase (RT); 92.77% for protease (PRO))," reported I. Derdelinckx and coauthors at the Catholic University of Leuven. "Discordance was mainly due to indeterminate reactions on LiPA (8.45% for RT;...
Source: Biotech Week (2004-01-14)
|
